announcing: Tipper

Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations

CONCLUSIONS: In overall performance, the PAT is at least comparable to the Myriad II and Penn II models in screening women appropriate for genetic referral. Simplicity and identification of families with non-BRCA hereditary BC syndromes suggest that the PAT is better suited for BC risk screening.

Pat Isenberg: Ovarian cancer is an elusive killer